Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world

BACKGROUND/AIMS: Previous studies have reported a high rate of sustained virologic response (SVR) and a low rate of serious adverse events with the use of daclatasvir (DCV) and asunaprevir (ASV) combination therapy. We evaluated the efficacy and safety of DCV and ASV combination therapy for patients...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Korean J Intern Med
Hlavní autoři: Oh, Jae Young, Kim, Byung Seok, Lee, Chang Hyeong, Song, Jeong Eun, Lee, Heon Ju, Park, Jung Gil, Hwang, Jae Seok, Chung, Woo Jin, Jang, Byoung Kuk, Kweon, Young Oh, Tak, Won Young, Park, Soo Young, Jang, Se Young, Suh, Jeong Ill, Kwak, Sang Gyu
Médium: Artigo
Jazyk:Inglês
Vydáno: The Korean Association of Internal Medicine 2019
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6610199/
https://ncbi.nlm.nih.gov/pubmed/29792020
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3904/kjim.2017.368
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky